Canton Hathaway LLC Trims Stock Position in Amgen Inc. (NASDAQ:AMGN)

Canton Hathaway LLC lowered its position in shares of Amgen Inc. (NASDAQ:AMGN) by 15.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,541 shares of the medical research company’s stock after selling 2,125 shares during the period. Amgen accounts for about 0.7% of Canton Hathaway LLC’s holdings, making the stock its 26th biggest position. Canton Hathaway LLC’s holdings in Amgen were worth $2,454,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the stock. State Street Corp grew its stake in Amgen by 0.8% during the second quarter. State Street Corp now owns 29,931,381 shares of the medical research company’s stock valued at $7,295,774,000 after acquiring an additional 238,297 shares in the last quarter. Morgan Stanley lifted its position in Amgen by 0.8% during the second quarter. Morgan Stanley now owns 10,040,932 shares of the medical research company’s stock valued at $2,447,476,000 after purchasing an additional 80,922 shares during the last quarter. Geode Capital Management LLC lifted its position in Amgen by 3.2% during the second quarter. Geode Capital Management LLC now owns 9,994,174 shares of the medical research company’s stock valued at $2,429,808,000 after purchasing an additional 313,744 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Amgen by 13.7% during the second quarter. Charles Schwab Investment Management Inc. now owns 7,242,037 shares of the medical research company’s stock valued at $1,765,247,000 after purchasing an additional 871,428 shares during the last quarter. Finally, Deutsche Bank AG lifted its position in Amgen by 8.6% during the second quarter. Deutsche Bank AG now owns 4,899,559 shares of the medical research company’s stock valued at $1,194,268,000 after purchasing an additional 386,976 shares during the last quarter. 74.95% of the stock is owned by institutional investors.

Several equities research analysts have issued reports on AMGN shares. Morgan Stanley dropped their target price on shares of Amgen from $251.00 to $235.00 and set an “equal weight” rating for the company in a research report on Tuesday, October 12th. Daiwa Capital Markets lowered shares of Amgen from an “outperform” rating to a “neutral” rating and set a $220.00 target price for the company. in a research report on Thursday, September 23rd. William Blair reiterated a “hold” rating on shares of Amgen in a research report on Friday, September 17th. Barclays lowered their price objective on shares of Amgen from $230.00 to $228.00 and set an “equal weight” rating for the company in a report on Wednesday, November 3rd. Finally, Oppenheimer lowered their price objective on shares of Amgen from $277.00 to $272.00 and set an “outperform” rating for the company in a report on Monday, November 1st. Two analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $235.50.

Shares of NASDAQ:AMGN traded down $0.56 during midday trading on Thursday, reaching $203.97. The company’s stock had a trading volume of 1,699,089 shares, compared to its average volume of 2,617,473. The company has a quick ratio of 1.36, a current ratio of 1.64 and a debt-to-equity ratio of 4.05. The firm has a 50 day moving average of $209.99 and a 200-day moving average of $227.76. The firm has a market capitalization of $114.89 billion, a P/E ratio of 21.01, a PEG ratio of 1.47 and a beta of 0.61. Amgen Inc. has a 12-month low of $200.47 and a 12-month high of $276.69.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 2nd. The medical research company reported $4.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $4.22 by $0.45. Amgen had a net margin of 21.77% and a return on equity of 108.67%. During the same period in the previous year, the firm earned $4.37 EPS. On average, research analysts predict that Amgen Inc. will post 16.83 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 8th. Investors of record on Tuesday, November 16th will be given a dividend of $1.76 per share. This represents a $7.04 dividend on an annualized basis and a yield of 3.45%. The ex-dividend date is Monday, November 15th. Amgen’s dividend payout ratio (DPR) is presently 72.50%.

Amgen Profile

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Read More: Cyclical Stocks – What You Should Know

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.